English, , 287kb
The aim of these guidelines is to propose a harmonised approach for the collection and analysis of biotechnology research and development (R&D) statistics in the government and higher education sectors.
This book reviews how the emergence of pharmacogenetics will impact the efficiency of pharmaceutical R&D and improve healthcare decision making and clinical care. It discusses what policies need to change in order for the public to reap the benefits from advances in diagnostic genetic testin
The ability to effectively use these vast amounts of knowledge will depend in part on the bringing together of different strands of information, data and biological materials within human biobanks and genetic research databases (HBGRDs).
The workshop discussed existing sector, national, or international approaches for assessment of sustainability of bio-based products, such as bio-based chemicals, bio-based plastics, enzymes, bio-based materials, and biofuels.
Synthetic biology is a transformative set of technologies which offer great opportunities for the construction of bioengineered parts, devices and microorganisms.
English, , 2,570kb
The 2009 edition brings together the latest available economic and activity data on biotechnology and innovation for 22 OECD members and four non-member countries. It builds on the extensive work of the OECD and national experts to improve the comparability of biotechnology statistics.
The impact of biotechnologies on medical research is intensifying. Because of new highly performing technologies, we are better able to understand and explore disease and drug mechanisms, which in turn could lead to major changes in the approach of patient care.
The focus at the OECD on industrial biotechnology is to identify the potential contribution of biotechnology to sustainable growth and development, and identify and appraise policy options for supply and demand side interventions that can drive efficient transition towards bio-based economy.
Genetics is playing an increasingly important role in health care. New technical advances and information deriving from human genome research are changing health care practices and the economics of healthcare provision.
This report presents the outcome of discussions held by the OECD member countries, together with a number of key partner countries, under the auspices of an expert Task Force established by the OECD Working Party on Biotechnology.